Quarterly ResultMar 29, 2026, 08:58 PM
Eli Lilly Q4 2025 Revenue Up 43% to $19.3 Billion, 2026 Revenue Guidance $80-$83 Billion
AI Summary
Eli Lilly reported strong Q4 2025 financial results, with revenue increasing 43% to $19.3 billion driven by Mounjaro and Zepbound. The company also issued 2026 revenue guidance in the range of $80 billion to $83 billion and non-GAAP EPS guidance of $33.50 to $35.00, indicating continued growth expectations.
Key Highlights
- Q4 2025 revenue increased 43% to $19.3 billion.
- Q4 2025 EPS increased 51% to $7.39 on a reported basis.
- 2026 revenue guidance issued in the range of $80 billion to $83 billion.
- FDA approved Kwikpen for tirzepatide and expanded indication for Jaypirca.
- Agreement with U.S. government to expand access to obesity medicines.